Madrigal Pharmaceuticals, Inc.
Symbol: MDGL
NASDAQ
229.84
USDMarktpreis heute
-12.1269
P/E-Verhältnis
-0.3892
PEG-Verhältnis
4.83B
MRK Kapital
- 0.00%
DIV Rendite
Madrigal Pharmaceuticals, Inc. (MDGL) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2001 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1494.38 | 634.1 | 358.8 | 270.3 | ||||||||||||||||||||||
balance-sheet.row.short-term-investments | 1141.9 | 534.2 | 27.2 | 234.1 | ||||||||||||||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.other-current-assets | 11.25 | 3.1 | 2.6 | 1.3 | ||||||||||||||||||||||
balance-sheet.row.total-current-assets | 1505.63 | 637.3 | 361.4 | 271.7 | ||||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 7.79 | 3.3 | 1.2 | 1.6 | ||||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 7.79 | 3.3 | 1.2 | 1.6 | ||||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.total-assets | 1513.42 | 640.5 | 362.6 | 273.3 | ||||||||||||||||||||||
balance-sheet.row.account-payables | 74.25 | 28 | 23.8 | 21.4 | ||||||||||||||||||||||
balance-sheet.row.short-term-debt | 2.1 | 0.5 | 0.6 | 0.4 | ||||||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 414.74 | 115.5 | 49.3 | 0.4 | ||||||||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||||||||
balance-sheet.row.other-current-liab | 339.92 | 90 | 91.5 | 55 | ||||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 415.93 | 116.7 | 49.3 | 0.4 | ||||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 4.09 | 1.2 | 0.6 | 0.8 | ||||||||||||||||||||||
balance-sheet.row.total-liab | 832.2 | 235.2 | 165.2 | 77.2 | ||||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.common-stock | 0.01 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.retained-earnings | -4725.3 | -1336.3 | -962.7 | -667.3 | ||||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0.25 | 0.5 | 0 | -0.1 | ||||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 5406.26 | 1741.2 | 1160.1 | 863.5 | ||||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 681.22 | 405.3 | 197.4 | 196.1 | ||||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1513.42 | 640.5 | 362.6 | 273.3 | ||||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.total-equity | 681.22 | 405.3 | 197.4 | 196.1 | ||||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 1513.42 | - | - | - | ||||||||||||||||||||||
Total Investments | 1141.9 | 534.2 | 27.2 | 234.1 | ||||||||||||||||||||||
balance-sheet.row.total-debt | 418.03 | 117.2 | 49.9 | 0.8 | ||||||||||||||||||||||
balance-sheet.row.net-debt | 65.56 | 17.3 | -281.7 | -35.5 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -373.63 | -373.6 | -295.4 | -241.8 | |||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0.53 | 0.5 | 0.5 | 0.4 | |||||||||||||||||||||
cash-flows.row.deferred-income-tax | -3.64 | -4.2 | 0 | -7.3 | |||||||||||||||||||||
cash-flows.row.stock-based-compensation | 49.73 | 49.7 | 31.6 | 26.9 | |||||||||||||||||||||
cash-flows.row.change-in-working-capital | -3.28 | -3.3 | 37.6 | 30.7 | |||||||||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.account-payables | 4.21 | 4.2 | 2.5 | 20.4 | |||||||||||||||||||||
cash-flows.row.other-working-capital | 11.49 | -7.5 | 35.2 | 10.3 | |||||||||||||||||||||
cash-flows.row.other-non-cash-items | 6.05 | 6.6 | 0.8 | 7.3 | |||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -324.23 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -1.48 | -1.5 | -0.2 | -0.2 | |||||||||||||||||||||
cash-flows.row.acquisitions-net | -1.85 | -5.5 | 0 | 0.8 | |||||||||||||||||||||
cash-flows.row.purchases-of-investments | -834.44 | -834.4 | -143.5 | -394.1 | |||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 333.4 | 333.4 | 350.4 | 389.3 | |||||||||||||||||||||
cash-flows.row.other-investing-activites | 1.85 | 5.5 | 0 | -0.8 | |||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -502.52 | -502.5 | 206.7 | -5.1 | |||||||||||||||||||||
cash-flows.row.debt-repayment | -64.64 | -64.6 | -49.1 | 0 | |||||||||||||||||||||
cash-flows.row.common-stock-issued | 504.4 | 530.5 | 255.4 | 170.2 | |||||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.other-financing-activites | 155.83 | 129.3 | 107.2 | 1 | |||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 595.12 | 595.1 | 313.5 | 171.2 | |||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 58.06 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.net-change-in-cash | -231.63 | -231.6 | 295.3 | -17.7 | |||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 352.47 | 99.9 | 331.5 | 36.3 | |||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 584.11 | 331.5 | 36.3 | 54 | |||||||||||||||||||||
cash-flows.row.operating-cash-flow | -324.23 | -324.2 | -224.9 | -183.9 | |||||||||||||||||||||
cash-flows.row.capital-expenditure | -1.48 | -1.5 | -0.2 | -0.2 | |||||||||||||||||||||
cash-flows.row.free-cash-flow | -325.71 | -325.7 | -225.1 | -184.1 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0.53 | 0.5 | 0.5 | 0.4 | |||||||||||||||||||||||
income-statement-row.row.gross-profit | -0.53 | -0.5 | -0.5 | -0.4 | |||||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
income-statement-row.row.research-development | 272.21 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 108.15 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0.3 | |||||||||||||||||||||||
income-statement-row.row.operating-expenses | 380.35 | 380 | 293.6 | 242.5 | |||||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 380.5 | 380.5 | 293.6 | 242.5 | |||||||||||||||||||||||
income-statement-row.row.interest-income | 19.58 | 19.6 | 2.2 | 0.4 | |||||||||||||||||||||||
income-statement-row.row.interest-expense | 5.7 | 12.7 | 4 | 0 | |||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 6.87 | 6.9 | -1.8 | 0.6 | |||||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0.3 | |||||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 6.87 | 6.9 | -1.8 | 0.6 | |||||||||||||||||||||||
income-statement-row.row.interest-expense | 5.7 | 12.7 | 4 | 0 | |||||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 4.3 | 0.5 | 2.2 | 0.4 | |||||||||||||||||||||||
income-statement-row.row.ebitda-caps | -372.9 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.operating-income | -380.5 | -380.5 | -293.6 | -242.5 | |||||||||||||||||||||||
income-statement-row.row.income-before-tax | -373.63 | -373.6 | -295.4 | -241.8 | |||||||||||||||||||||||
income-statement-row.row.income-tax-expense | 4.19 | 0 | 4 | -0.8 | |||||||||||||||||||||||
income-statement-row.row.net-income | -374.53 | -373.6 | -299.3 | -241.1 |
Häufig gestellte Frage
Wie hoch ist die Madrigal Pharmaceuticals, Inc. (MDGL) Gesamtvermögen?
Madrigal Pharmaceuticals, Inc. (MDGL) Gesamtvermögen ist 640547000.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist N/A.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.000.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist -16.483.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist 0.000.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist 0.000.
Was ist der Madrigal Pharmaceuticals, Inc. (MDGL) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist -373630000.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 117193000.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 379969000.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 99915000.000.